<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the terms of the Creative Commons Attribution License Abstract Coronavirus" exact="disease" post="2019 (COVID-19) caused by the severe acute respiratory syndrome"/>
 <result pre="License Abstract Coronavirus disease 2019 (COVID-19) caused by the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious"/>
 <result pre="Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection"/>
 <result pre="Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is a highly contagious infection that"/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious" exact="infection" post="that may break the healthcare system of several countries."/>
 <result pre="new treatments based on current knowledge of the mechanism of" exact="infection" post="and potential targets within. Finally, we also discuss patent"/>
 <result pre="discovery replication cycle drug targets fig-count: table-count: ref-count: Epidemiology Coronavirus" exact="disease" post="2019 (COVID-19) caused by the severe acute respiratory syndrome"/>
 <result pre="ref-count: Epidemiology Coronavirus disease 2019 (COVID-19) caused by the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious"/>
 <result pre="Epidemiology Coronavirus disease 2019 (COVID-19) caused by the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious disease"/>
 <result pre="Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is a highly contagious disease that"/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious" exact="disease" post="that may break the healthcare system of several countries."/>
 <result pre="The transmission can occur among humans via oral and nasal" exact="respiratory" post="droplets and contact with contaminated surfaces.2 For instance, droplets"/>
 <result pre="two Wuhan hospitals in China.4 The results showed that the" exact="viral" post="RNA level in ventilated patient wards was low because"/>
 <result pre="ventilated, and medical staff areas had elevated concentrations of airborne" exact="viral" post="RNA. After rigorous sanitisation procedures these levels were reduced."/>
 <result pre="of maintaining social isolation. They also suggested that in the" exact="absence of" post="such restrictions, the pandemic could last until 2024. Thus,"/>
 <result pre="context, the search for new medicines available to combat this" exact="disease" post="is urgent. Etiological agent Coronaviruses are members of the"/>
 <result pre="coronavirus (229E, NL63) or beta coronavirus [OC43, HKU1, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
 <result pre="(229E, NL63) or beta coronavirus [OC43, HKU1, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and"/>
 <result pre="coronavirus [OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and more recently the SARS-CoV-2]."/>
 <result pre="[OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and more recently the SARS-CoV-2]. 229E,"/>
 <result pre="HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and more recently the SARS-CoV-2]. 229E, NL63,"/>
 <result pre="recently the SARS-CoV-2]. 229E, NL63, OC43, and HKU1 can cause" exact="upper" post="and lower respiratory tract infection in adults and children."/>
 <result pre="SARS-CoV-2]. 229E, NL63, OC43, and HKU1 can cause upper and" exact="lower" post="respiratory tract infection in adults and children. After the"/>
 <result pre="229E, NL63, OC43, and HKU1 can cause upper and lower" exact="respiratory" post="tract infection in adults and children. After the 2000s,"/>
 <result pre="OC43, and HKU1 can cause upper and lower respiratory tract" exact="infection" post="in adults and children. After the 2000s, two epidemic"/>
 <result pre="2012, respectively.15,16 In 2019, after the first report of novel" exact="pneumonia" post="(COVID-19) in Wuhan, China, the seventh hCoV was described."/>
 <result pre="China, the seventh hCoV was described. It also causes severe" exact="acute" post="respiratory syndrome (therefore called SARS-CoV-2) and spreads very quickly"/>
 <result pre="the seventh hCoV was described. It also causes severe acute" exact="respiratory" post="syndrome (therefore called SARS-CoV-2) and spreads very quickly worldwide"/>
 <result pre="seventh hCoV was described. It also causes severe acute respiratory" exact="syndrome" post="(therefore called SARS-CoV-2) and spreads very quickly worldwide ."/>
 <result pre="mediates coronavirus entry into host cells via fusion of the" exact="viral" post="and cellular membranes through a pre to post fusion"/>
 <result pre="(APN) in MERS or others alphacoronaviruses like TGEV (porcine transmissible" exact="gastroenteritis" post="coronavirus) and porcine respiratory coronavirus (PRCH).18,19,20 Other structural proteins"/>
 <result pre="others alphacoronaviruses like TGEV (porcine transmissible gastroenteritis coronavirus) and porcine" exact="respiratory" post="coronavirus (PRCH).18,19,20 Other structural proteins are mandatory to assemble"/>
 <result pre="coronavirus (PRCH).18,19,20 Other structural proteins are mandatory to assemble the" exact="complete" post="viral particle like nucleocapsid protein (N), membrane protein (M)"/>
 <result pre="(PRCH).18,19,20 Other structural proteins are mandatory to assemble the complete" exact="viral" post="particle like nucleocapsid protein (N), membrane protein (M) and"/>
 <result pre="is derived from A by two mutations T8782C and C28144T," exact="type C" post="differs from its parent type B by mutation of"/>
 <result pre="mutations T8782C and C28144T, type C differs from its parent" exact="type B" post="by mutation of G26144T. The A and C types"/>
 <result pre="In December 2019, COVID-19 was initially reported as a new" exact="viral pneumonia," post="due to the clinical characteristics of the large number"/>
 <result pre="of cases that emerged in Wuhan, China.25,26 SARS-CoV-2 typically causes" exact="respiratory" post="sickness, the major clinical characteristics observed in infected patients"/>
 <result pre="recruited by the immune system leading to the destruction of" exact="type I" post="and type II alveolar epithelial cells causing a collapse"/>
 <result pre="immune system leading to the destruction of type I and" exact="type II" post="alveolar epithelial cells causing a collapse of the alveoli"/>
 <result pre="to the destruction of type I and type II alveolar" exact="epithelial" post="cells causing a collapse of the alveoli function and"/>
 <result pre="type I and type II alveolar epithelial cells causing a" exact="collapse" post="of the alveoli function and consequently the acute respiratory"/>
 <result pre="causing a collapse of the alveoli function and consequently the" exact="acute" post="respiratory distress syndrome (ARDS). In the severe condition, with"/>
 <result pre="a collapse of the alveoli function and consequently the acute" exact="respiratory" post="distress syndrome (ARDS). In the severe condition, with an"/>
 <result pre="of the alveoli function and consequently the acute respiratory distress" exact="syndrome" post="(ARDS). In the severe condition, with an increase of"/>
 <result pre="rich fluid from lungs enter in the bloodstream causing the" exact="systemic" post="inflammatory syndrome (SIRS).29,30 These complicating factors can lead to"/>
 <result pre="from lungs enter in the bloodstream causing the systemic inflammatory" exact="syndrome" post="(SIRS).29,30 These complicating factors can lead to a multi-organ"/>
 <result pre="These complicating factors can lead to a multi-organ failure and" exact="septic shock," post="causing patient death. Furthermore, some pre-existing conditions can enhance"/>
 <result pre="disease, including age over 60 years and a history of" exact="chronic" post="diseases like chronic lung disease, asthma, heart diseases, immunosuppressed"/>
 <result pre="over 60 years and a history of chronic diseases like" exact="chronic" post="lung disease, asthma, heart diseases, immunosuppressed patients, cancer, diabetes"/>
 <result pre="60 years and a history of chronic diseases like chronic" exact="lung disease," post="asthma, heart diseases, immunosuppressed patients, cancer, diabetes or chronic"/>
 <result pre="a history of chronic diseases like chronic lung disease, asthma," exact="heart" post="diseases, immunosuppressed patients, cancer, diabetes or chronic kidney disease.31,32,33,34,35"/>
 <result pre="like chronic lung disease, asthma, heart diseases, immunosuppressed patients, cancer," exact="diabetes" post="or chronic kidney disease.31,32,33,34,35 Finally, the vast majority of"/>
 <result pre="chronic lung disease, asthma, heart diseases, immunosuppressed patients, cancer, diabetes" exact="or chronic" post="kidney disease.31,32,33,34,35 Finally, the vast majority of people have"/>
 <result pre="lung disease, asthma, heart diseases, immunosuppressed patients, cancer, diabetes or" exact="chronic" post="kidney disease.31,32,33,34,35 Finally, the vast majority of people have"/>
 <result pre="to the market have been estimated to be ten times" exact="lower" post="and the time is shortened by around a half,"/>
 <result pre="scratch: the reduced time and financial investment for development, the" exact="lower" post="risk of failure and a consolidated pharmaceutical supply chain"/>
 <result pre="following topic, we will review SARS-CoV-2 structure and mechanism of" exact="infection" post="in order to discuss molecular targets from the virus"/>
 <result pre="are more advanced in clinical studies. SARS-CoV-2: structure, mechanism of" exact="infection" post="and drug targets SARS-CoV-2 structure - Electron microscopy imaging"/>
 <result pre="Mpro (Nsp5) protease and RdRp (Nsp12) RNA polymerase, which form" exact="viral" post="replicase/transcriptase complexes (RTCs), and are encapsulated in double-layered vesicles"/>
 <result pre="the endoplasmic reticulum (ER).56,57,58 Fig. 1: genomic structure of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and its encoded proteins."/>
 <result pre="endoplasmic reticulum (ER).56,57,58 Fig. 1: genomic structure of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and its encoded proteins. Together,"/>
 <result pre="reticulum (ER).56,57,58 Fig. 1: genomic structure of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and its encoded proteins. Together, open"/>
 <result pre="first ones have a crucial role in the assembly of" exact="viral" post="particles and virus invasion.56,58 The main structural proteins are"/>
 <result pre="tissue tropism and pathogenesis.58,60 E proteins exert several roles in" exact="virus infection," post="such as helping in virus assembly and release from"/>
 <result pre="instance, the stabilisation of N protein-RNA complexes.56,63 SARS-CoV-2 mechanism of" exact="infection" post="- At present, the mechanisms that underlie SARS-CoV-2 infection"/>
 <result pre="of infection - At present, the mechanisms that underlie SARS-CoV-2" exact="infection" post="have not been directly described. Nonetheless, they seem to"/>
 <result pre="similar to those proposed for other coronaviruses.58 In one proposal," exact="virus infection" post="starts with the binding of its S proteins to"/>
 <result pre="to those proposed for other coronaviruses.58 In one proposal, virus" exact="infection" post="starts with the binding of its S proteins to"/>
 <result pre="the fusion of virus and cell membranes that culminates in" exact="viral" post="gRNA release into the cytoplasm. This event is proposed"/>
 <result pre="dependent on the availability of these proteases.59,64,65 Fig. 2: severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) replication cycle and potential"/>
 <result pre="on the availability of these proteases.59,64,65 Fig. 2: severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) replication cycle and potential targets"/>
 <result pre="the availability of these proteases.59,64,65 Fig. 2: severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) replication cycle and potential targets for"/>
 <result pre="replication cycle and potential targets for drug repurposing. (1) Virus" exact="infection" post="initiates with the binding of virus S proteins to"/>
 <result pre="(gRNA) is liberated into the cytoplasm after the fusion between" exact="viral" post="and cell cytoplasmic membranes, an event triggered by membrane"/>
 <result pre="ribbon) are transcribed. (5) The subgenomic RNAs are translated into" exact="viral" post="structural and accessory proteins in the cytosol. (6) Upon"/>
 <result pre="into ER and follow the secretory pathway to the ER-Golgi" exact="intermediate" post="compartment (ERGIC). (7) Meanwhile, a copy of the gRNA"/>
 <result pre="(9) The new virion travels through the cytoplasm inside a" exact="vesicle" post="and leaves the cell by exocytosis. (10) Alternatively, in"/>
 <result pre="blue arrows indicate the gRNA movement through the cycle. Some" exact="viral" post="and host proteins have been explored as potential targets"/>
 <result pre="cycle.44,59,66,67 Once in the cytoplasm, gRNA is readily translated into" exact="viral" post="polyproteins (pp1a/pp1ab), which are cleaved into the individual Nsps"/>
 <result pre="E and M structural proteins are driven to the ER-Golgi" exact="intermediate" post="compartment (ERGIC) where S proteins go through post-translational modifications"/>
 <result pre="into the ERGIC. In this compartment, nucleocapsid and the other" exact="viral" post="proteins are assembled into a virion which travels through"/>
 <result pre="into a virion which travels through the cytoplasm inside a" exact="vesicle" post="and leaves the cell by exocytosis.48,56,59 Candidate drug targets"/>
 <result pre="- In the search for a treatment for COVID-19, several" exact="viral" post="and host molecular proteins have been explored as potential"/>
 <result pre="drug targets. Overall, they participate in key events of the" exact="virus infection" post="cycle, such as cell entry and replication, as well"/>
 <result pre="targets. Overall, they participate in key events of the virus" exact="infection" post="cycle, such as cell entry and replication, as well"/>
 <result pre="compounds 1-14 are shown in Fig. 4. Fig. 3: severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) 3D"/>
 <result pre="1-14 are shown in Fig. 4. Fig. 3: severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) 3D structure"/>
 <result pre="are shown in Fig. 4. Fig. 3: severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) main protease (Mpro) 3D structure (PDB"/>
 <result pre="drug repurposing candidates and compounds 1-14 under investigation against coronavirus" exact="disease" post="2019 (COVID-19). Nsp3 is the largest protein encoded by"/>
 <result pre="immune response of the host.85 These functions are pivotal for" exact="virus infection" post="justifying the search for SARS-CoVs PLpro inhibitors.84,86,87,88,89,90 Putative inhibitors"/>
 <result pre="response of the host.85 These functions are pivotal for virus" exact="infection" post="justifying the search for SARS-CoVs PLpro inhibitors.84,86,87,88,89,90 Putative inhibitors"/>
 <result pre="(6) (a tyrosine kinase inhibitor used in the treatment of" exact="chronic" post="immune thrombocytopenia) and natural products [e.g., platycodin D (7)].89,91"/>
 <result pre="(7)].89,91 Fig. 5: tertiary structure and catalytic site of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (PDB 6W9C, 2.7"/>
 <result pre="Fig. 5: tertiary structure and catalytic site of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) PLpro (PDB 6W9C, 2.7 Ã…)."/>
 <result pre="5: tertiary structure and catalytic site of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) PLpro (PDB 6W9C, 2.7 Ã…). (A)"/>
 <result pre="Nsp12) is an essential protein responsible for RNA synthesis during" exact="viral" post="RNA transcription and replication cycles.89 As described for SARS-CoV,"/>
 <result pre="(10), a synthetic guanosine nucleoside indicated for the treatment of" exact="hepatitis C" post="virus (HCV) infection.97,98 The crucial role of RdRp and"/>
 <result pre="target for anti-CoVs agents.93 Fig. 6: 3D structure of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (PDB"/>
 <result pre="for anti-CoVs agents.93 Fig. 6: 3D structure of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (PDB 7BV2,"/>
 <result pre="anti-CoVs agents.93 Fig. 6: 3D structure of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (PDB 7BV2, 2.5"/>
 <result pre="distance and the RTP molecule (pink) are represented as sticks." exact="Magnesium" post="ions (pink) are represented as space filling spheres. Images"/>
 <result pre="helicase.74,103,104,105 They include drugs used in the clinics to treat" exact="acquired immunodeficiency syndrome" post="(AIDS), such as vapreotide (11) (somatostatin analog) and atazanavir"/>
 <result pre="They include drugs used in the clinics to treat acquired" exact="immunodeficiency" post="syndrome (AIDS), such as vapreotide (11) (somatostatin analog) and"/>
 <result pre="include drugs used in the clinics to treat acquired immunodeficiency" exact="syndrome" post="(AIDS), such as vapreotide (11) (somatostatin analog) and atazanavir"/>
 <result pre="treatment of gastrointestinal diseases].103,104,106 Fig. 7: tertiary structure of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) helicase (PDB 6JYT, 2.8 Ã…,"/>
 <result pre="of gastrointestinal diseases].103,104,106 Fig. 7: tertiary structure of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) helicase (PDB 6JYT, 2.8 Ã…, Nsp13)."/>
 <result pre="gastrointestinal diseases].103,104,106 Fig. 7: tertiary structure of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) helicase (PDB 6JYT, 2.8 Ã…, Nsp13). The"/>
 <result pre="N7 position of RNA 5â€™-guanosine forming the 5â€™-cap structure of" exact="viral" post="RNAs.108 Additionally, Nsp14 also has a catalytic domain in"/>
 <result pre="shown in Fig. 10. Fig. 8: tertiary structure of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) Nsp14 (PDB 5C8S, 3.3 Ã…)"/>
 <result pre="in Fig. 10. Fig. 8: tertiary structure of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) Nsp14 (PDB 5C8S, 3.3 Ã…) in"/>
 <result pre="Fig. 10. Fig. 8: tertiary structure of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) Nsp14 (PDB 5C8S, 3.3 Ã…) in complex"/>
 <result pre="Fig. 9: ribbon representation and VdW surface of the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) 2â€™-O-methyltransferase 3D structure (PDB"/>
 <result pre="9: ribbon representation and VdW surface of the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) 2â€™-O-methyltransferase 3D structure (PDB 6W61,"/>
 <result pre="ribbon representation and VdW surface of the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) 2â€™-O-methyltransferase 3D structure (PDB 6W61, 2.0"/>
 <result pre="drug repurposing candidates and compounds 15-29 under investigation against coronavirus" exact="disease" post="2019 (COVID-19). Spike protein (S) is a viral type"/>
 <result pre="against coronavirus disease 2019 (COVID-19). Spike protein (S) is a" exact="viral" post="type I transmembrane glycoprotein (~180-200 kDa) responsible for CoVs"/>
 <result pre="coronavirus disease 2019 (COVID-19). Spike protein (S) is a viral" exact="type I" post="transmembrane glycoprotein (~180-200 kDa) responsible for CoVs interaction and"/>
 <result pre="into three main domains: an extracellular, a transmembrane and a" exact="short" post="intracellular domain (Fig. 11).117 The former protrudes from the"/>
 <result pre="11: tertiary and quaternary structure of extracellular domain of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein (PDB: 6VXX,"/>
 <result pre="tertiary and quaternary structure of extracellular domain of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) S protein (PDB: 6VXX, 2.8"/>
 <result pre="and quaternary structure of extracellular domain of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) S protein (PDB: 6VXX, 2.8 Ã…)."/>
 <result pre="homeostasis, as well induce inflammatory response, which may lead to" exact="pulmonary" post="damage.123,124 Thus, the use of inhibitors of IC activity"/>
 <result pre="by the FDA-approved drugs gliclazide (17), a sulfonylurea administered to" exact="non-insulin-dependent diabetes mellitus" post="patients, and memantine (18), an N-methyl-D-aspartate receptor antagonist used"/>
 <result pre="the FDA-approved drugs gliclazide (17), a sulfonylurea administered to non-insulin-dependent" exact="diabetes mellitus" post="patients, and memantine (18), an N-methyl-D-aspartate receptor antagonist used"/>
 <result pre="proteins.126 Host cell targets - A key step in SARS-CoVs" exact="infection" post="is the attachment of S protein to host angiotensin-converting"/>
 <result pre="angiotensin-(1-9) and angiotensin-(1-7) peptides, respectively.127 ACE2 is expressed in the" exact="upper" post="respiratory system, type I and II alveolar epithelial cells"/>
 <result pre="and angiotensin-(1-7) peptides, respectively.127 ACE2 is expressed in the upper" exact="respiratory" post="system, type I and II alveolar epithelial cells in"/>
 <result pre="peptides, respectively.127 ACE2 is expressed in the upper respiratory system," exact="type I" post="and II alveolar epithelial cells in the lungs, heart,"/>
 <result pre="in the upper respiratory system, type I and II alveolar" exact="epithelial" post="cells in the lungs, heart, endothelial cells, kidney tubular"/>
 <result pre="e.g., losartan (22)], are commonly used in clinics to treat" exact="hypertension" post="and cardiovascular/renal diseases.132,133 Recently, some researchers have debated over"/>
 <result pre="(family: S1 clan: PA).69,138 It is highly expressed in the" exact="epithelial" post="cells of the prostate, and relatively less in lungs,"/>
 <result pre="an interesting therapeutic target since its inhibitors could potentially block" exact="virus infection" post="in its initial stages.65,138 Potential TMPRSS2 blockers include some"/>
 <result pre="interesting therapeutic target since its inhibitors could potentially block virus" exact="infection" post="in its initial stages.65,138 Potential TMPRSS2 blockers include some"/>
 <result pre="3-[[5-(3-fluorophenyl)pyrimidin-2-yl]amino~(N)-(4-methyl phenyl)benzamide]] and natural products [e.g., withanone (25)].65,139,140,141 In the" exact="absence of" post="exogenous or membrane-bound proteases (e g. TMPRSS2) to promote"/>
 <result pre="exogenous or membrane-bound proteases (e g. TMPRSS2) to promote SARS-CoVs" exact="infection" post="on cellsâ€™ surface, the virus can also be internalised"/>
 <result pre="the fusion activity of S protein and subsequent insertion of" exact="viral" post="SARS-CoV gRNA into the cytosol, especially in cells with"/>
 <result pre="viral SARS-CoV gRNA into the cytosol, especially in cells with" exact="lower" post="expression of TMPRSS2.64,65 Some key elements of endocytosis have"/>
 <result pre="as the main inducer of fever, inflammation and of hepatic" exact="acute" post="phase proteins. Therefore, IL-6/IL-6R antagonists have a therapeutic effect"/>
 <result pre="COVID-19 treatment may be beneficial to avoid the â€œcytokines stormâ€�" exact="syndrome" post="that some patients with the severe form of the"/>
 <result pre="syndrome that some patients with the severe form of the" exact="disease" post="may develop.147 This deleterious event is caused by an"/>
 <result pre="Apart from SARS-CoVs infection, some relevant molecular targets of other" exact="viral" post="diseases and host metabolism have also been investigated in"/>
 <result pre="have also been investigated in COVID-19 drug discovery, such as" exact="viral" post="neuraminidases and the DPP4 cell receptor. Neuraminidases (NA) or"/>
 <result pre="facilitating its release from infected cells.150 Its critical role in" exact="virus infection" post="and proliferation has been exploited by NA inhibitors [e.g.,"/>
 <result pre="its release from infected cells.150 Its critical role in virus" exact="infection" post="and proliferation has been exploited by NA inhibitors [e.g.,"/>
 <result pre="influenza season in China when the etiologic agent of this" exact="disease" post="was yet unknown. So far, there is no evidence"/>
 <result pre="complexing protein 2 or T-cell activation antigen CD26, is a" exact="type II" post="transmembrane glycoprotein of 766 aa largely expressed in many"/>
 <result pre="of COVID-19.152,153,155,156 In principle, these inhibitors could be beneficial for" exact="type 2" post="diabetes patients (or even without diabetes) with COVID-19 since"/>
 <result pre="In principle, these inhibitors could be beneficial for type 2" exact="diabetes" post="patients (or even without diabetes) with COVID-19 since it"/>
 <result pre="and compounds in clinical trials to explore possible interactions with" exact="viral" post="proteins.75,159,160 Artificial intelligence (AI) methods are also being extensively"/>
 <result pre="approaches can even explore hidden connections between drugs, human and" exact="viral" post="targets to find novel bioactivities and even combinations of"/>
 <result pre="TABLE I In silico studies of drug repurposing for coronavirus" exact="disease" post="2019 (COVID-19) Repurposed drug Previous use Predicted targets Discovery"/>
 <result pre="(32), eriodictyol (33), cepharanthine (34), ergoloid (35) and hypericin (36)" exact="Multiple" post="Disrupting spike protein (S-protein) and ACE2 receptor interaction or"/>
 <result pre="hypericin (36) have shown antiviral activity against coronaviruses, including severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV).a 160 Mefuparib hydrochloride (CVL218) (37)"/>
 <result pre="(36) have shown antiviral activity against coronaviruses, including severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV).a 160 Mefuparib hydrochloride (CVL218) (37) Cancer"/>
 <result pre="have shown antiviral activity against coronaviruses, including severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV).a 160 Mefuparib hydrochloride (CVL218) (37) Cancer Nucleocapsid"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV).a 160 Mefuparib hydrochloride (CVL218) (37)" exact="Cancer" post="Nucleocapsid (N protein) Knowledge-graph docking in vitro and in"/>
 <result pre="and have shown inhibitory activity against Mpro.b 103 Baricitinib (39)" exact="Rheumatoid arthritis" post="Human AP2-associated protein kinase 1 (AAK1) Knowledge-graph A pilot"/>
 <result pre="have shown inhibitory activity against Mpro.b 103 Baricitinib (39) Rheumatoid" exact="arthritis" post="Human AP2-associated protein kinase 1 (AAK1) Knowledge-graph A pilot"/>
 <result pre="patients.c 161 Toremifene (40), sirolimus (41), mercaptopurine (42), irbesartan (43)" exact="Multiple" post="Multiple targets in humans and coronaviruses Systems pharmacology-based network"/>
 <result pre="161 Toremifene (40), sirolimus (41), mercaptopurine (42), irbesartan (43) Multiple" exact="Multiple" post="targets in humans and coronaviruses Systems pharmacology-based network and"/>
 <result pre="drug repurposing candidates and compounds 30-49 under investigation against coronavirus" exact="disease" post="2019 (COVID-19). Ge and coworkers constructed a virus-related knowledge"/>
 <result pre="protein-protein interactions, molecule similarity and sequence similarity of human and" exact="viral" post="sources to predict drugs targeting SARS-CoV-2.164 Well known biological"/>
 <result pre="of IL-6 induced by the CpG oligodeoxynucleotide 1826 (CPG-ODN1826) in" exact="peripheral" post="blood mononuclear cells (PMBC) indicating it might be an"/>
 <result pre="of the P2-associated protein kinase 1 (AAK1), a regulator of" exact="viral" post="endocytosis in AT2 alveolar epithelial cells.161 Inhibitors of AAK1"/>
 <result pre="1 (AAK1), a regulator of viral endocytosis in AT2 alveolar" exact="epithelial" post="cells.161 Inhibitors of AAK1 could then potentially block viral"/>
 <result pre="alveolar epithelial cells.161 Inhibitors of AAK1 could then potentially block" exact="viral" post="entry into alveolar cells. However, the authors argued that"/>
 <result pre="The premise is that protein targets that are associated with" exact="viral" post="infections are part of a subnetwork of the human"/>
 <result pre="premise is that protein targets that are associated with viral" exact="infections" post="are part of a subnetwork of the human protein-protein"/>
 <result pre="that the selected molecules and targets have reported links to" exact="viral infection" post="and some have been used for treatment of Coronavirus-related"/>
 <result pre="the selected molecules and targets have reported links to viral" exact="infection" post="and some have been used for treatment of Coronavirus-related"/>
 <result pre="be explored for generating new avenues for further research. Heterologous" exact="viral" post="protein expression could be used in a myriad of"/>
 <result pre="ideal animal model of COVID-19 should reflect the clinical signs," exact="viral" post="replication and pathology reported in humans.193In vivo animal infection"/>
 <result pre="signs, viral replication and pathology reported in humans.193In vivo animal" exact="infection" post="experiments with SARS-CoV-2 require infrastructure of a biosafety level"/>
 <result pre="vitro and in vivo studies of drug repurposing for coronavirus" exact="disease" post="2019 (COVID-19) Repurposed drug Previous use Targets In vitro"/>
 <result pre="polymerase 0.77 Î¼M 129.9 194 Chloroquine (20) / Hydroxychloroquine (26)" exact="Malaria" post="/ Lupus and rheumatoid arthritis Acidification in endosomes and"/>
 <result pre="Î¼M 129.9 194 Chloroquine (20) / Hydroxychloroquine (26) Malaria /" exact="Lupus" post="and rheumatoid arthritis Acidification in endosomes and lysosomes, glycosylation"/>
 <result pre="194 Chloroquine (20) / Hydroxychloroquine (26) Malaria / Lupus and" exact="rheumatoid arthritis" post="Acidification in endosomes and lysosomes, glycosylation of cellular virus"/>
 <result pre="Chloroquine (20) / Hydroxychloroquine (26) Malaria / Lupus and rheumatoid" exact="arthritis" post="Acidification in endosomes and lysosomes, glycosylation of cellular virus"/>
 <result pre="to 100.8 / 14.4 to 61.5 depending on multiplicities of" exact="infection" post="194,195,196 Ritonavir (2) + lopinavir (1) HIV 3-chymotrypsin-like protease"/>
 <result pre="developed by Gilead Sciences Inc. to fight Ebola, acts on" exact="viral" post="replication by inhibiting RNA polymerase.96 This molecule was also"/>
 <result pre="against SARS and MERS viruses.200,201,202 Wang et al. demonstrated reduced" exact="viral" post="copy numbers in cell culture supernatant of Vero E6"/>
 <result pre="presence of varying concentrations of Remdesivir (8).194 This compound blocked" exact="virus infection" post="at low-micromolar concentration (EC50 = 0.77 Î¼M) and showed"/>
 <result pre="of varying concentrations of Remdesivir (8).194 This compound blocked virus" exact="infection" post="at low-micromolar concentration (EC50 = 0.77 Î¼M) and showed"/>
 <result pre="(&amp;gt; 100). The authors also disclosed that remdesivir (8) inhibited" exact="virus infection" post="efficiently in human liver cancer Huh-7 cells. Chloroquine (CQ;"/>
 <result pre="100). The authors also disclosed that remdesivir (8) inhibited virus" exact="infection" post="efficiently in human liver cancer Huh-7 cells. Chloroquine (CQ;"/>
 <result pre="disclosed that remdesivir (8) inhibited virus infection efficiently in human" exact="liver cancer" post="Huh-7 cells. Chloroquine (CQ; 20) and its less toxic"/>
 <result pre="that remdesivir (8) inhibited virus infection efficiently in human liver" exact="cancer" post="Huh-7 cells. Chloroquine (CQ; 20) and its less toxic"/>
 <result pre="less toxic derivative, hydroxychloroquine (HCQ; 26), are used to treat" exact="malaria" post="and lupus/rheumatoid arthritis, respectively. Both drugs have already been"/>
 <result pre="(26) is also being studied in vitro as a SARS-CoV-2" exact="infection" post="inhibitor acting on both virus entry, as well as"/>
 <result pre="the two compounds against an in vitro model of SARS-CoV-2" exact="infection" post="on Vero E6 cells, demonstrated that CQ (20) is"/>
 <result pre="more potent than HCQ (26) at four different multiplicities of" exact="infection" post="(0.01, 0.02, 0.2 and 0.8): EC50 2.71, 3.81, 7.14"/>
 <result pre="copy numbers in the cell supernatant at 48 h post" exact="infection" post="were measured. The authors also measured the cytotoxicity of"/>
 <result pre="more potent than CQ (20) to inhibit in vitro SARS-CoV-2" exact="infection" post="(EC50 0.72 vs 5.47 Î¼M).196 The authors also performed"/>
 <result pre="used together with other antiretrovirals for the treatment of human" exact="immunodeficiency" post="virus since the beginning of the century.209 Ritonavir (2)"/>
 <result pre="manner.210 The Mpro plays a major role in homeostasis of" exact="viral" post="polyproteins essential for viral function and replication, being considered"/>
 <result pre="a major role in homeostasis of viral polyproteins essential for" exact="viral" post="function and replication, being considered a validated drug target.211"/>
 <result pre="main protease, an enzyme essential in processing polyproteins translated from" exact="viral" post="RNA.212 Choy et al. demonstrated that it inhibits SARS-CoV-2"/>
 <result pre="when added to Vero-hSLAM cells 2 h post-infection and measuring" exact="viral" post="RNA at 48h post-infection.198 Teicoplanin (27), an antibiotic used"/>
 <result pre="at 48h post-infection.198 Teicoplanin (27), an antibiotic used against gram-positive" exact="bacterial infections," post="was found to be active in vitro against SARS-CoV-2"/>
 <result pre="pipeline comprising in vitro, and in vivo models of SARS-CoV-2" exact="infection" post="is particularly important to identify new antivirals for human"/>
 <result pre="from: https://clinicaltrials.gov/ct2/results?cond=COVID-19). With a growing number of patients suffering from" exact="acute" post="severe respiratory symptoms and hospital capacities reaching its limit,"/>
 <result pre="With a growing number of patients suffering from acute severe" exact="respiratory" post="symptoms and hospital capacities reaching its limit, therapeutic options"/>
 <result pre="day. TABLE III Clinical studies of drug repurposing for coronavirus" exact="disease" post="2019 (COVID-19) Repurposed drug Study characteristics Estimated enrolment Dosage"/>
 <result pre="plus 100 mg once daily, for more nine consecutive days" exact="Adult" post="patients with mild and moderate COVID-19, no published results"/>
 <result pre="epidemic control in China with no eligible patients) 237 patients" exact="Adult" post="patients with severe COVID-19, remdesivir (8) was not associated"/>
 <result pre="no eligible patients) 1063 patients Remdesivir (8) treated patients with" exact="lower" post="respiratory tract infection have a shorter time to recovery"/>
 <result pre="eligible patients) 1063 patients Remdesivir (8) treated patients with lower" exact="respiratory" post="tract infection have a shorter time to recovery compared"/>
 <result pre="1063 patients Remdesivir (8) treated patients with lower respiratory tract" exact="infection" post="have a shorter time to recovery compared to placebo"/>
 <result pre="hydroxychloroquine (26) daily for 10 days Hydroxychloroquine (26) significantly reduces" exact="viral" post="load despite small sample size 219 Ritonavir (2)/lopinavir (1)"/>
 <result pre="than the previous works cited above) enrolled 1063 patients with" exact="lower" post="respiratory tract infection, demonstrated that individuals that were treated"/>
 <result pre="the previous works cited above) enrolled 1063 patients with lower" exact="respiratory" post="tract infection, demonstrated that individuals that were treated with"/>
 <result pre="15 days).216 Even with a small scientific ballast, due to" exact="limited" post="information about safety and effectiveness of using remdesivir (8),"/>
 <result pre="by promising in vitro data that suggested an impairment of" exact="viral" post="replication by acting on endosome-mediated viral entry or later"/>
 <result pre="suggested an impairment of viral replication by acting on endosome-mediated" exact="viral" post="entry or later phases of viral replication.194,226 Both molecules"/>
 <result pre="by acting on endosome-mediated viral entry or later phases of" exact="viral" post="replication.194,226 Both molecules have a well-studied toxicity profile being"/>
 <result pre="than half-century as antimalarials, but in some cases can induce" exact="heart" post="side effects.227 These drugs have already been examined against"/>
 <result pre="of COVID-19 were performed.217 Based on results for a very" exact="limited" post="number of patients (100), it was concluded that CQ"/>
 <result pre="important to note that both doses studied were above the" exact="Brazilian" post="recommended dose. A controversial study performed by Gautret et"/>
 <result pre="that HCQ (26) treatment daily at 600 mg significantly decreases" exact="viral" post="load in COVID-19 patients and its effect is reinforced"/>
 <result pre="no significant difference in any of the parameters evaluated: the" exact="primary" post="endpoint of 28-day mortality, hazard ratio and hospital stay"/>
 <result pre="have already been reported, encouraging its testing in SARS-CoV-2.235 A" exact="total" post="of 199 patients confirmed severe SARS-CoV-2 infection were randomly"/>
 <result pre="in SARS-CoV-2.235 A total of 199 patients confirmed severe SARS-CoV-2" exact="infection" post="were randomly designated to be given either (1)/(2) (400"/>
 <result pre="promising, no benefit was observed on clinical improvement, mortality and" exact="viral" post="loads on severe COVID-19 patients. Other clinical trials are"/>
 <result pre="SOLIDARITY megatrial. Sheahan et al. demonstrated that this combination improves" exact="pulmonary" post="function but does not reduce virus replication or severe"/>
 <result pre="of MERS-CoV.236 This combination also showed promising results in MERS-CoV" exact="Infection" post="in a Nonhuman Primate Model.233 The study (NCT04276688) administered"/>
 <result pre="beta 1b and the base therapeutic treatment in Moderate to" exact="Severe" post="COVID-19. Currently, there is a lot of research around"/>
 <result pre="synchronised clinical trials with randomised, double-blind, placebo-controlled are still needed." exact="Infection" post="prevention by social distancing and supportive medical care, are"/>
 <result pre="medical care, are the only strategies to deal with this" exact="disease" post="until this moment. Patent protection and synthesis of repositionable"/>
 <result pre="only strategies to deal with this disease until this moment." exact="Patent" post="protection and synthesis of repositionable drugs The goal of"/>
 <result pre="is the drug remdesivir (8), which was developed by the" exact="American" post="pharmaceutical company Gilead Sciences, Inc. in 2011. Nowadays, (8)"/>
 <result pre="(Family 2), the use of remdesivir (8) in treating Coronaviridae" exact="infection" post="(Family 3), among other patents that claims the use"/>
 <result pre="use of (8) for the treatment of a series of" exact="viral" post="infections (Families 3 and 4) (Fig. 13).241 Practically, this"/>
 <result pre="of (8) for the treatment of a series of viral" exact="infections" post="(Families 3 and 4) (Fig. 13).241 Practically, this means"/>
 <result pre="7 of 4-chloro-7H- pyrrolo[2,3-d]pyrimidine (50) using 2-(trimethylsilyl)ethoxymethyl chloride (51), affording" exact="intermediate" post="(52). Next step is a Suzuki-Miyaura reaction, coupling the"/>
 <result pre="system to a 4-pyrazoleboronic acid pinacol ester (53), giving key" exact="intermediate" post="(54). Parallelly, a couple of steps starting from 2-(chloromethyl)oxirane"/>
 <result pre="1-Boc-3-azetidinone (58) that reacts with diethyl cyanomethylphosphonate (59), affording key" exact="intermediate" post="(60). Next, the key intermediates (54) and (60) react"/>
 <result pre="the oxidation step can be performed under flow conditions. Then," exact="intermediate" post="(67) is reacted with ester (53), affording (68). A"/>
 <result pre="during a pandemic. Consequently, it would be difficult to ensure" exact="short" post="term global availability of the treatment, since the production"/>
 <result pre="the starting material (2-isopropylthiazol-4-yl)- nitro-methylamine (71) and N-[(2,2,2-trichloroethoxy)carbonyl]-L-valine (72), generating" exact="intermediate" post="(73). The intermediate is mixed with p-toluenesulfonyl chloride and"/>
 <result pre="(2-isopropylthiazol-4-yl)- nitro-methylamine (71) and N-[(2,2,2-trichloroethoxy)carbonyl]-L-valine (72), generating intermediate (73). The" exact="intermediate" post="is mixed with p-toluenesulfonyl chloride and triethylamine to activate"/>
 <result pre="in a one-pot procedure. The condensation allows the formation of" exact="intermediate" post="(75), which is submitted to acidic conditions for a"/>
 <result pre="by Abbott are similar, involving the synthesis of a key" exact="intermediate" post="amino alcohol unit, that is then connected to the"/>
 <result pre="yield, baricitinib (39) has the highest number of steps and" exact="lower" post="overall yield when compared to ritonavir (2) and lopinavir"/>
 <result pre="cost-effective of the three of them. In conclusion - SARS-CoV-2" exact="infection" post="is a life-threatening disease with such a high transmission"/>
 <result pre="of them. In conclusion - SARS-CoV-2 infection is a life-threatening" exact="disease" post="with such a high transmission rate that can surpass"/>
 <result pre="vaccines are the ideal solution for preventing the spread of" exact="infectious diseases" post="like COVID-19 their development cycle have intrinsic challenges and"/>
 <result pre="safety checking steps that require several months or years to" exact="complete" post="their development. A similar situation is found for developing"/>
 <result pre="pathology of COVID-19 as well as structural information on the" exact="viral" post="and host proteins involved in the infection mechanism. This"/>
 <result pre="information on the viral and host proteins involved in the" exact="infection" post="mechanism. This knowledge is essential for allowing researchers to"/>
 <result pre="great promise in finding occult links between drugs, human and" exact="viral" post="targets to find novel bioactivities and even combinations of"/>
 <result pre="into clinical efficacy and safety. At the moment, even with" exact="limited" post="information about safety and effectiveness, remdesivir is the only"/>
 <result pre="supported by CAPES (Finance code 001). References REFERENCES 1collab: WHOCoronavirus" exact="disease" post="(COVID-2019) situation report 198; 2020https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 2KampfGTodtDPfaenderSSteinmannEPersistence of coronaviruses on"/>
 <result pre="inactivation with biocidal agentsJ Hosp Infect2020104324625132035997 3BourouibaLTurbulent gas clouds and" exact="respiratory" post="pathogen emissions potential implications for reducing transmission of COVID-19JAMA2020323181837183832215590"/>
 <result pre="concept for the wastewater surveillance of COVID-19 in the communitySci" exact="Total" post="Environ202072813876413876432387778 7collab: FIOCRUZFiocruz divulga estudo sobre a presenÃ§a do"/>
 <result pre="for virus origins and receptor bindingLancet20203951022456557432007145 11AlmazÃ¡nFSolaIZuÃ±igaSMarquez-JuradoSMoralesLBecaresMCoronavirus reverse genetic systems" exact="infectious" post="clones and repliconsVirus Res201418926227024930446 12WooPCYLauSKPLamCSFLauCCYTsangAKLLauJHNDiscovery of seven novel mammalian"/>
 <result pre="the gene source of gammacoronavirus and deltacoronavirusJ Virol20128673995400822278237 13KandeilAGomaaMShehataMEl-TaweelAKayedAEAbiadhAMiddle East" exact="Respiratory" post="Syndrome coronavirus infection in non-camelid domestic mammalsEmerg Microbes Infect20198110310830866764"/>
 <result pre="gene source of gammacoronavirus and deltacoronavirusJ Virol20128673995400822278237 13KandeilAGomaaMShehataMEl-TaweelAKayedAEAbiadhAMiddle East Respiratory" exact="Syndrome" post="coronavirus infection in non-camelid domestic mammalsEmerg Microbes Infect20198110310830866764 14TyrrellDABynoeMCultivation"/>
 <result pre="of gammacoronavirus and deltacoronavirusJ Virol20128673995400822278237 13KandeilAGomaaMShehataMEl-TaweelAKayedAEAbiadhAMiddle East Respiratory Syndrome coronavirus" exact="infection" post="in non-camelid domestic mammalsEmerg Microbes Infect20198110310830866764 14TyrrellDABynoeMCultivation of viruses"/>
 <result pre="(dpp4) implications for the origin and emergence of Middle East" exact="Respiratory" post="Syndrome coronavirusVirol J201310130430424107353 17de WildeAHSnijderEJKikkertMvan HemertMJ.Host factors in coronavirus"/>
 <result pre="implications for the origin and emergence of Middle East Respiratory" exact="Syndrome" post="coronavirusVirol J201310130430424107353 17de WildeAHSnijderEJKikkertMvan HemertMJ.Host factors in coronavirus replication."/>
 <result pre="of SARS-CoV-2 genomesProc Natl Acad Sci USA2020117179241924332269081 25ZhouPYang X-LWang X-GHuBZhangLZhangWA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="bat originNature2020579779827027332015507 26WuFZhaoSYuBChen Y-MWangWSong Z-GA new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature2020579779826526932015508 27MenniCValdesAMFreidinMBSudreCHNguyenLHDrewDAReal-time tracking of self-reported symptoms to"/>
 <result pre="originNature2020579779827027332015507 26WuFZhaoSYuBChen Y-MWangWSong Z-GA new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature2020579779826526932015508 27MenniCValdesAMFreidinMBSudreCHNguyenLHDrewDAReal-time tracking of self-reported symptoms to predict"/>
 <result pre="COVID-19 a systematic review and meta-analysisTravel Med Infect Dis20203410162310162332179124 29LiGFanYLaiYHanTLiZZhouPCoronavirus" exact="infections" post="and immune responsesJ Med Virol202092442443231981224 30BarnesBJAdroverJMBaxter-StoltzfusABorczukACools-LartigueJCrawfordJMTargeting potential drivers of"/>
 <result pre="in Italy and ChinaJ Infect Dev Ctries2020140212512832146445 32CookTMThe importance of" exact="hypertension" post="as a risk factor for severe illness and mortality"/>
 <result pre="33DengYLiuWLiuKFang Y-YShangJZhouLClinical characteristics of fatal and recovered cases of coronavirus" exact="disease" post="2019 in Wuhan, China a retrospective studyChin Med J"/>
 <result pre="Clin Nurs20202913-142044204632239784 36ZhangJWuSXuLAsymptomatic carriers of COVID-19 as a concern for" exact="disease" post="prevention and control more testing, more follow-upBiosci Trends202014320620832321904 37AshburnTTThorKBDrug"/>
 <result pre="Drug Discov202019314915032127666 44KupferschmidtKCohenJRace to find COVID-19 treatments acceleratesScience202036764851412141332217705 45ChhikaraBSRathiBSinghJFNUPCoronavirus SARS-CoV-2" exact="disease" post="COVID-19 infection, prevention and clinical advances of the prospective"/>
 <result pre="of the prospective chemical drug therapeutics: a Review on Coronavirus" exact="disease" post="COVID-19, epidemiology, prevention, and anticipated therapeutic advancesChem Biol Lett2020716372"/>
 <result pre="therapeutic advancesChem Biol Lett2020716372 46ZhuNZhangDWangWLiXYangBSongJA novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773331978945 47CalyLDruceJRobertsJBondKTranTKosteckiRIsolation and rapid"/>
 <result pre="first patient diagnosed with COVID-19 in AustraliaMed J Aust20202121045946232237278 48ShereenMAKhanSKazmiABashirNSiddiqueRCOVID-19" exact="infection" post="origin, transmission, and characteristics of human coronavirusesJ Adv Res202024919832257431"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 52ZhouYHouYShenJHuangYMartinWChengFNetwork-based drug repurposing for"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 52ZhouYHouYShenJHuangYMartinWChengFNetwork-based drug repurposing for"/>
 <result pre="drug repurposingNature2020583781645946832353859 55KhailanyRASafdarMOzaslanMGenomic characterization of a novel SARS-CoV-2Gene Rep20201910068210068232300673 56AstutiIYsrafilSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) an overview of viral"/>
 <result pre="repurposingNature2020583781645946832353859 55KhailanyRASafdarMOzaslanMGenomic characterization of a novel SARS-CoV-2Gene Rep20201910068210068232300673 56AstutiIYsrafilSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) an overview of viral structure"/>
 <result pre="55KhailanyRASafdarMOzaslanMGenomic characterization of a novel SARS-CoV-2Gene Rep20201910068210068232300673 56AstutiIYsrafilSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) an overview of viral structure and"/>
 <result pre="56AstutiIYsrafilSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an overview of" exact="viral" post="structure and host responseDiabetes Metab Syndr202014440741232335367 57QiuYXuKFunctional studies of"/>
 <result pre="nonstructural proteinsSTEMedicine202012e39 58WangSZhangYLiuSPengHMackeyVSunLCoronaviruses and the associated potential therapeutics for the" exact="viral" post="infectionsJ Infect Dis Ther20208218 59TangTBidonMJaimesJAWhittakerGRDanielSCoronavirus membrane fusion mechanism offers"/>
 <result pre="CoVs to SARS-CoV-2 moving toward more biased codon usage in" exact="viral" post="structural and nonstructural genesJ Med Virol202092666066632159237 63HuangJSongWHuangHSunQPharmacological therapeutics targeting"/>
 <result pre="by a clinically proven protease inhibitorCell20201812 66SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic treatments for Coronavirus" exact="disease" post="2019 (COVID-19)JAMA2020323181824183632282022 67BoopathiSPomaABKolandaivelP.Novel 2019 coronavirus structure, mechanism of action,"/>
 <result pre="Acids Res201947D1 72Wang H-MLiang P-HPharmacophores and biological activities of severe" exact="acute" post="respiratory syndrome viral protease inhibitorsExpert Opin Ther Pat2007175533546 73JinZZhaoYSunYZhangBWangHWuYStructural"/>
 <result pre="Res201947D1 72Wang H-MLiang P-HPharmacophores and biological activities of severe acute" exact="respiratory" post="syndrome viral protease inhibitorsExpert Opin Ther Pat2007175533546 73JinZZhaoYSunYZhangBWangHWuYStructural basis"/>
 <result pre="72Wang H-MLiang P-HPharmacophores and biological activities of severe acute respiratory" exact="syndrome" post="viral protease inhibitorsExpert Opin Ther Pat2007175533546 73JinZZhaoYSunYZhangBWangHWuYStructural basis for"/>
 <result pre="H-MLiang P-HPharmacophores and biological activities of severe acute respiratory syndrome" exact="viral" post="protease inhibitorsExpert Opin Ther Pat2007175533546 73JinZZhaoYSunYZhangBWangHWuYStructural basis for the"/>
 <result pre="Genomics202047211912132173287 79MaCSaccoMDHurstBTownsendJAHuYSzetoTBoceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2" exact="viral" post="replication by targeting the viral main proteaseCell Res202030867869232541865 80ShamsiAMohammadTAnwarSAlAjmiMFHussainARehmanMTGlecaprevir"/>
 <result pre="inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the" exact="viral" post="main proteaseCell Res202030867869232541865 80ShamsiAMohammadTAnwarSAlAjmiMFHussainARehmanMTGlecaprevir and Maraviroc are high-affinity inhibitors"/>
 <result pre="J-YJeongHJKimJHKimYMPark S-JKimDDiarylheptanoids from Alnus japonica inhibit papain-like protease of severe" exact="acute" post="respiratory Syndrome coronavirusBiol Pharm Bull201235112036204222971649 88Lin M-HMosesDCHsieh C-HCheng S-CChen"/>
 <result pre="S-JKimDDiarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute" exact="respiratory" post="Syndrome coronavirusBiol Pharm Bull201235112036204222971649 88Lin M-HMosesDCHsieh C-HCheng S-CChen Y-HSun"/>
 <result pre="from Alnus japonica inhibit papain-like protease of severe acute respiratory" exact="Syndrome" post="coronavirusBiol Pharm Bull201235112036204222971649 88Lin M-HMosesDCHsieh C-HCheng S-CChen Y-HSun C-YDisulfiram"/>
 <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ Biol Chem2020295206785679732284326"/>
 <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ Biol Chem2020295206785679732284326 97DuYChenXFavipiravir"/>
 <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ Biol Chem2020295206785679732284326 97DuYChenXFavipiravir pharmacokinetics"/>
 <result pre="100Keum Y-SJeong Y-JDevelopment of chemical inhibitors of the SARS coronavirus" exact="viral" post="helicase as a potential targetBiochem Pharmacol201284101351135822935448 101JiaZYanLRenZWuLWangJGuoJDelicate structural coordination"/>
 <result pre="a potential targetBiochem Pharmacol201284101351135822935448 101JiaZYanLRenZWuLWangJGuoJDelicate structural coordination of the severe" exact="acute" post="respiratory syndrome coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400"/>
 <result pre="potential targetBiochem Pharmacol201284101351135822935448 101JiaZYanLRenZWuLWangJGuoJDelicate structural coordination of the severe acute" exact="respiratory" post="syndrome coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400 102Yu"/>
 <result pre="targetBiochem Pharmacol201284101351135822935448 101JiaZYanLRenZWuLWangJGuoJDelicate structural coordination of the severe acute respiratory" exact="syndrome" post="coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400 102Yu M-SLeeJLeeJMKimYChin"/>
 <result pre="cleavage site predicted in the spike protein of the novel" exact="pneumonia" post="coronavirus (2019-nCoV) potentially related to viral transmissibilityVirol Sin202035333733932198713 118FantiniJDi"/>
 <result pre="protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to" exact="viral" post="transmissibilityVirol Sin202035333733932198713 118FantiniJDi ScalaCChahinianHYahiNStructural and molecular modelling studies reveal"/>
 <result pre="paramyxoviruses new targets for antivirals?Viruses2015762858288326053927 121Jimenez-GuardeÃ±oJMNieto-TorresJLDeDiegoMLRegla-NavaJAFernandez-DelgadoRCastaÃ±o-RodriguezCThe PDZ-binding motif of severe" exact="acute" post="respiratory syndrome coronavirus envelope protein is a determinant of"/>
 <result pre="new targets for antivirals?Viruses2015762858288326053927 121Jimenez-GuardeÃ±oJMNieto-TorresJLDeDiegoMLRegla-NavaJAFernandez-DelgadoRCastaÃ±o-RodriguezCThe PDZ-binding motif of severe acute" exact="respiratory" post="syndrome coronavirus envelope protein is a determinant of viral"/>
 <result pre="targets for antivirals?Viruses2015762858288326053927 121Jimenez-GuardeÃ±oJMNieto-TorresJLDeDiegoMLRegla-NavaJAFernandez-DelgadoRCastaÃ±o-RodriguezCThe PDZ-binding motif of severe acute respiratory" exact="syndrome" post="coronavirus envelope protein is a determinant of viral pathogenesisPLoS"/>
 <result pre="acute respiratory syndrome coronavirus envelope protein is a determinant of" exact="viral" post="pathogenesisPLoS Pathog2014108e100432025122212 122GuptaMKVemulaSDondeRGoudaGBeheraLVaddeRIn-silico approaches to detect inhibitors of the"/>
 <result pre="Pathog2014108e100432025122212 122GuptaMKVemulaSDondeRGoudaGBeheraLVaddeRIn-silico approaches to detect inhibitors of the human severe" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channel.J Biomol Struct"/>
 <result pre="122GuptaMKVemulaSDondeRGoudaGBeheraLVaddeRIn-silico approaches to detect inhibitors of the human severe acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channel.J Biomol Struct Dyn202010.1080/07391102.2020.1751300"/>
 <result pre="approaches to detect inhibitors of the human severe acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channel.J Biomol Struct Dyn202010.1080/07391102.2020.1751300 123PervushinKTanEParthasarathyKLinXJiangFLYuDStructure"/>
 <result pre="SARS coronavirus envelope protein ion channel Baric RSPLoS Pathog200957e100051119593379 124Nieto-TorresJLDeDiegoMLVerdiÃ¡-BÃ¡guenaCJimenez-GuardeÃ±oJMRegla-NavaJAFernandez-DelgadoRSevere" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channel activity promotes"/>
 <result pre="coronavirus envelope protein ion channel Baric RSPLoS Pathog200957e100051119593379 124Nieto-TorresJLDeDiegoMLVerdiÃ¡-BÃ¡guenaCJimenez-GuardeÃ±oJMRegla-NavaJAFernandez-DelgadoRSevere acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channel activity promotes virus"/>
 <result pre="envelope protein ion channel Baric RSPLoS Pathog200957e100051119593379 124Nieto-TorresJLDeDiegoMLVerdiÃ¡-BÃ¡guenaCJimenez-GuardeÃ±oJMRegla-NavaJAFernandez-DelgadoRSevere acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channel activity promotes virus fitness"/>
 <result pre="fitness and pathogenesisPLoS Pathog2014105e100407724788150 125KhanSSiddiqueRShereenMAAliALiuJBaiQEmergence of a novel coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus 2 biology and therapeutic optionsJ Clin"/>
 <result pre="and pathogenesisPLoS Pathog2014105e100407724788150 125KhanSSiddiqueRShereenMAAliALiuJBaiQEmergence of a novel coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus 2 biology and therapeutic optionsJ Clin Microbiol2020585122"/>
 <result pre="pathogenesisPLoS Pathog2014105e100407724788150 125KhanSSiddiqueRShereenMAAliALiuJBaiQEmergence of a novel coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus 2 biology and therapeutic optionsJ Clin Microbiol2020585122 126Singh"/>
 <result pre="Biophys Res Commun20205301101432828269 127McKinneyCAFattahCLoughreyCMMilliganGNicklinSAAngiotensin-(1-7) and angiotensin-(1-9) function in cardiac and" exact="vascular" post="remodellingClin Sci (Lond)20141261281582724593683 128MuniyappaRGubbiSCOVID-19 pandemic, coronaviruses, and diabetes mellitusAm"/>
 <result pre="cardiac and vascular remodellingClin Sci (Lond)20141261281582724593683 128MuniyappaRGubbiSCOVID-19 pandemic, coronaviruses, and" exact="diabetes" post="mellitusAm J Physiol Endocrinol Metab20203185E736E74132228322 129ZhangHPenningerJMLiYZhongNSlutskyASAngiotensin-converting enzyme 2 (ACE2)"/>
 <result pre="Internet]STI-1499, a potent anti-SARS-CoV-22020antibodydemonstrates ability to completely inhibit in vitro" exact="virus infection" post="in preclinical studies 131DevauxCARolain J-MColsonPRaoultDNew insights on the antiviral"/>
 <result pre="a potent anti-SARS-CoV-22020antibodydemonstrates ability to completely inhibit in vitro virus" exact="infection" post="in preclinical studies 131DevauxCARolain J-MColsonPRaoultDNew insights on the antiviral"/>
 <result pre="system receptorsCurr Hypertens Rep2020223222232114685 133Zheng Y-YMa Y-TZhang J-YXieXCOVID-19 and the" exact="cardiovascular" post="systemNat Rev Cardiol202017525926032139904 134Zheng Y-YMa Y-TZhang J-YXieXReply to 'interaction"/>
 <result pre="of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur" exact="Heart" post="J202041191801180332196087 138ShenLWMaoHJWuYLTanakaYZhangWTMPRSS2 a potential target for treatment of influenza"/>
 <result pre="consider IL-6 receptor antagonist for the therapy of cytokine storm" exact="syndrome" post="in SARS-CoV-2 infected patients.J Med Virol202010.1002/jmv.26078 149LombardVRamuluHGDrulaECoutinhoPMHenrissatBThe carbohydrate-active enzymes"/>
 <result pre="Acids Res201442D1D490D49524270786 150McAuleyJLGilbertsonBPTrifkovicSBrownLEMcKimm-BreschkinJLInfluenza virus neuraminidase structure and functionsFront Microbiol2019102393930761095 151DruckerDJCoronavirus" exact="infections" post="and type 2 diabetes - shared pathways with therapeutic"/>
 <result pre="150McAuleyJLGilbertsonBPTrifkovicSBrownLEMcKimm-BreschkinJLInfluenza virus neuraminidase structure and functionsFront Microbiol2019102393930761095 151DruckerDJCoronavirus infections and" exact="type 2" post="diabetes - shared pathways with therapeutic implicationsEndocr Rev2020413457470 152StrolloRPozzilliPDPP4"/>
 <result pre="neuraminidase structure and functionsFront Microbiol2019102393930761095 151DruckerDJCoronavirus infections and type 2" exact="diabetes" post="- shared pathways with therapeutic implicationsEndocr Rev2020413457470 152StrolloRPozzilliPDPP4 inhibition:"/>
 <result pre="shared pathways with therapeutic implicationsEndocr Rev2020413457470 152StrolloRPozzilliPDPP4 inhibition: preventing SARS-CoV-2" exact="infection" post="and/or progression of COVID-19?Diabetes Metab Res Rev202010.1002/dmrr.3330 153IacobellisGCOVID-19 and"/>
 <result pre="infection and/or progression of COVID-19?Diabetes Metab Res Rev202010.1002/dmrr.3330 153IacobellisGCOVID-19 and" exact="diabetes" post="Can DPP4 inhibition play a role?Diabetes Res Clin Pract202016210812510812532224164"/>
 <result pre="Today202025592894132320852 159SmithMSmithJCRepurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2" exact="viral" post="spike protein and viral spike protein-human ACE2 interface2020https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/11871402 160PantSSinghMRavichandiranVMurtyUSNSrivastavaHKPeptide-like"/>
 <result pre="COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and" exact="viral" post="spike protein-human ACE2 interface2020https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/11871402 160PantSSinghMRavichandiranVMurtyUSNSrivastavaHKPeptide-like and small-molecule inhibitors against"/>
 <result pre="Covid-19J Biomol Struct Dyn2020110 161RichardsonPGriffinITuckerCSmithDOechsleOPhelanABaricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet202039510223e30e3132032529 162BungNKrishnanSRBulusuGRoyA.De novo design of new chemical entities"/>
 <result pre="Biomol Struct Dyn2020110 161RichardsonPGriffinITuckerCSmithDOechsleOPhelanABaricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet202039510223e30e3132032529 162BungNKrishnanSRBulusuGRoyA.De novo design of new chemical entities (NCEs)"/>
 <result pre="165KimDEMinJSJangMSLeeJYShinYSParkCMNatural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43" exact="infection" post="of MRC-5 human lung cellsBiomolecules2019911696696 166JoSKimSShinDHKim M-SInhibition of SARS-CoV"/>
 <result pre="Inhib Med Chem202035114515131724441 167YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe" exact="acute" post="respiratory syndrome coronavirus into host cellsJ Virol20047820113341133915452254 168Fintelman-RodriguesNSacramentoCQLimaCRda SilvaFSFerreiraACMattosMet"/>
 <result pre="Med Chem202035114515131724441 167YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe acute" exact="respiratory" post="syndrome coronavirus into host cellsJ Virol20047820113341133915452254 168Fintelman-RodriguesNSacramentoCQLimaCRda SilvaFSFerreiraACMattosMet al.Atazanavir"/>
 <result pre="Chem202035114515131724441 167YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe acute respiratory" exact="syndrome" post="coronavirus into host cellsJ Virol20047820113341133915452254 168Fintelman-RodriguesNSacramentoCQLimaCRda SilvaFSFerreiraACMattosMet al.Atazanavir inhibits"/>
 <result pre="Group of the International Committee on Taxonomy of VirusesThe species" exact="Severe" post="acute respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it"/>
 <result pre="of the International Committee on Taxonomy of VirusesThe species Severe" exact="acute" post="respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2Nat"/>
 <result pre="the International Committee on Taxonomy of VirusesThe species Severe acute" exact="respiratory" post="syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2Nat Microbiol20205453654432123347"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 197Choy K-TWong"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 197Choy K-TWong AY-LKaewpreedeePSiaSFChenDHuiKPYRemdesivir,"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020711573273932150618 197Choy K-TWong AY-LKaewpreedeePSiaSFChenDHuiKPYRemdesivir, lopinavir,"/>
 <result pre="201SheahanTPSimsACZhouSGrahamRLPruijssersAJAgostiniMLAn orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in miceSci Transl Med202012541"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol Res Perspect201751e0029328596841 206LiuJCaoRXuMWangXZhangHHuHHydroxychloroquine, a less toxic derivative of"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061161632194981 207McChesneyEWAnimal toxicity and pharmacokinetics of hydroxychloroquine"/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="Respiratory" post="Syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 214KalilACTreating"/>
 <result pre="compound library identifies four small-molecule inhibitors of Middle East Respiratory" exact="Syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 214KalilACTreating COVID-19"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends2020141727332074550 218BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMEffect of high vs low"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier J-CParolaPHoangVTMeddebLMailheMHydroxychloroquine"/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier J-CParolaPHoangVTMeddebLMailheMHydroxychloroquine and"/>
 <result pre="J Med2020382191787179932187464 221MulanguSDoddLEDaveyRTTshiani MbayaOProschanMMukadiDA randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN Engl J Med2019381242293230331774950 222HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHFirst case of 2019 novel"/>
 <result pre="225collab: FDARemdesivir EUA letter of authorization2020https://www.fda.gov/media/137564/download 226SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on" exact="viral" post="infections an old drug against today's diseasesLancet Infect Dis200331172272714592603"/>
 <result pre="FDARemdesivir EUA letter of authorization2020https://www.fda.gov/media/137564/download 226SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on viral" exact="infections" post="an old drug against today's diseasesLancet Infect Dis200331172272714592603 227ChatreCRoubilleFVernhetHJorgensenCPers"/>
 <result pre="activity of azithromycin and use in COVID-19Clin Pharmacol Ther2020108220121132302411 229MehraMRDesaiSSKuySHenryTDPatelANRetraction" exact="cardiovascular disease," post="drug therapy, and mortality in Covid-19N Engl J Med20203822625822582"/>
 <result pre="JF-WYaoYYeung M-LDengWBaoLJiaLTreatment with lopinavir/ritonavir or interferon-ÃŸ1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="announce collaboration for development and commercialization of oral anti-inflammatory and" exact="autoimmune" post="therapies2009https://investor.incyte.com/news-releases/news-release-details/lilly-and-incyte-announce-collaboration-development-and 244collab: ClinicalTrials.govSearch results: baricitinib | COVID-192020https://clinicaltrials.gov/ct2/results?cond=COVID-19&amp;amp;term=baricitinib&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 245Kobierski MEinventorsLillyElicollab:"/>
</results>
